KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Common Equity (2016 - 2025)

Gsk (GSK) has 8 years of Common Equity data on record, last reported at $17.5 billion in Q4 2024.

  • For Q4 2024, Common Equity rose 5.92% year-over-year to $17.5 billion; the TTM value through Dec 2024 reached $17.5 billion, up 5.92%, while the annual FY2024 figure was $17.5 billion, 5.26% up from the prior year.
  • Common Equity reached $17.5 billion in Q4 2024 per GSK's latest filing, up from $16.6 billion in the prior quarter.
  • Across five years, Common Equity topped out at $20.3 billion in Q4 2021 and bottomed at $12.4 billion in Q4 2022.
  • Average Common Equity over 4 years is $16.7 billion, with a median of $17.1 billion recorded in 2023.
  • Peak YoY movement for Common Equity: tumbled 38.75% in 2022, then soared 33.26% in 2023.
  • A 4-year view of Common Equity shows it stood at $20.3 billion in 2021, then crashed by 38.75% to $12.4 billion in 2022, then skyrocketed by 33.26% to $16.6 billion in 2023, then increased by 5.92% to $17.5 billion in 2024.
  • Per Business Quant database, its latest 3 readings for Common Equity were $17.5 billion in Q4 2024, $16.6 billion in Q4 2023, and $12.4 billion in Q4 2022.